Salute e Benessere
Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst Advancements in Treatment Options | DelveInsight
Discover the gastrointestinal neuroendocrine tumors new treatment @
The total number of incident cases of GI-NETs in the US was nearly in 2024 and is projected to increase by 2034 due to improved diagnostic capabilities and enhanced imaging and endoscopic techniques, which enable earlier and more accurate detection of these tumors.
Innovations in diagnostic tools, including advanced imaging techniques and biomarker identification, have improved the accuracy of GI-NET detection. These advancements enable clinicians to identify tumors at earlier stages, resulting in improved patient outcomes and contributing to market growth.
The expected launch of GI-NET therapies, such as (ITM Solucin GmbH), (Camurus), (Actinium-225 DOTATATE) (Bristol Myers Squibb/RayzeBio), and others, is expected to change the market dynamics in the coming years.
The treatment landscape for gastrointestinal neuroendocrine tumors continues to focus primarily on symptom management and disease control rather than achieving a cure. Somatostatin analogs, including , remain the standard of care for both functional and nonfunctional NETs, helping to suppress hormone production and slow tumor progression in well-differentiated cases. Radioligand therapies, such as have broadened treatment options for somatostatin receptor–positive tumors by providing targeted therapy with demonstrated improvements in progression-free survival. Emerging radiopharmaceuticals, like , show promise for enhanced tumor targeting and improved safety. Nevertheless, significant challenges persist, particularly in treating receptor-negative tumors, high-grade neuroendocrine carcinomas, and cases with extensive metastasis or resistance to first-line therapies.
There is a growing shift toward more precise, biologically informed treatment approaches. Next-generation somatostatin receptor modulators, such as , aim to enhance targeting and tolerability. Concurrent advances in diagnostic technologies, including gene expression assays such as the NETest and circulating tumor biomarkers, offer potential for earlier detection and real-time monitoring of disease. Collectively, these developments signal a move toward multimodal, mechanism-driven care that combines targeted radiotherapy, immunotherapy, and precision diagnostics. However, most of these therapies are still in early-phase trials, and no current treatment fully addresses aggressive or poorly differentiated NETs. Continued research is crucial for developing safer, more effective, and personalized strategies for managing this complex and often underappreciated group of tumors.
To know more about gastrointestinal neuroendocrine tumors treatment options, visit @
Some of the GI-NET therapies in clinical trials include (ITM Solucin GmbH), (Camurus), (Actinium-225 DOTATATE) (Bristol Myers Squibb/RayzeBio), and others.
is an advanced targeted radionuclide therapy composed of two molecular parts: Edotreotide (DOTATOC), a somatostatin analog derived from octreotide, and EndolucinBeta, a no-carrier-added (n.c.a.) lutetium-177 chloride, a synthetic therapeutic radioisotope that emits low-energy beta particles. The therapy received orphan drug designation for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following positive Phase II clinical results, which showed significant clinical benefit characterized by low uptake in normal tissues and a high tumor-to-kidney ratio.
Currently, ITM-11 is being assessed in two pivotal Phase III trials, COMPETE (NCT03049189) and COMPOSE (NCT04919226). The COMPETE trial is investigating its efficacy in patients with Grade 1 and Grade 2 GEP-NETs, while COMPOSE is evaluating its potential in well-differentiated high-grade Grade 2 and Grade 3 GEP-NETs.
Meanwhile, is a long-acting subcutaneous octreotide depot formulation in development for acromegaly, GEP-NET, and polycystic liver disease (PLD). The pivotal Phase III SORENTO study, a randomized, active-controlled trial, is assessing the efficacy and safety of CAM2029 in GEP-NET patients and is expected to conclude its randomized phase in early 2026. In parallel, preparations for the commercial launch of CAM2029 in GEP-NET are underway.
The anticipated launch of these emerging therapies are poised to transform the gastrointestinal neuroendocrine tumors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the gastrointestinal neuroendocrine tumors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for gastrointestinal neuroendocrine tumors @
Gastrointestinal neuroendocrine tumors (GI-NETs) are a distinct subtype of neuroendocrine tumors (NETs). Like other cancers, they are named based on their site of origin; for instance, a NET that begins in the gastrointestinal (GI) tract is referred to as a GI-NET, which represents the primary tumor. When it spreads to other organs, it is referred to as secondary cancer. GI-NETs typically develop in the GI tract, most commonly in the rectum, small intestine, or appendix. Common symptoms include abdominal pain, a noticeable lump under the skin, unusual fatigue, and weight loss.
The staging system for GI-NETs varies slightly depending on the site. Generally, it ranges from stage 1 to stage 4, with higher stages indicating more advanced and more difficult-to-treat disease. Some types may also have substages that describe the extent of cancer spread more precisely. GI-NETs can behave either indolently or aggressively. The World Health Organization (WHO) has developed a specific classification system for categorizing these tumors. While the exact cause remains unclear, several risk factors have been associated with GI-NETs, including pituitary adenomas, Von Hippel–Lindau (VHL) syndrome, and pheochromocytomas. These tumors often grow slowly, and in some cases, may remain stable for months or even years, meaning immediate treatment may not always be necessary.
The gastrointestinal neuroendocrine tumors epidemiology section provides insights into the historical and current gastrointestinal neuroendocrine tumors patient pool and forecasted trends for the leading markets. In the US, the overall incidence of GI-NETs was with hindgut tumors being the most common. Hindgut, foregut, and midgut GI-NETs represented of cases, respectively.
The gastrointestinal neuroendocrine tumors market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Download the report to understand which factors are driving gastrointestinal neuroendocrine tumors therapeutics market trends @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine tumors companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gastroenteropancreatic neuroendocrine tumors companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gastric neuroendocrine tumors companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEJ-NET companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gastrointestinal-neuroendocrine-tumors-market-set-to-surge-by-2034-amidst-advancements-in-treatment-options--delveinsight-302584358.html